Director of EMBL-EBI and Senior Scientist
Rolf Apweiler is Director of EMBL-EBI, together with Ewan Birney. Prior to this position he was Joint Associate Director, after many years of leading protein resources such as UniProt. Rolf has made a major contribution to methods for the automatic annotation of proteins, making it possible to add relevant information to proteome sets for entire organisms. He has spearheaded the development of standards for proteomics data, and his teams have maintained major collections of protein identifications from proteomics experiments (PRIDE) and molecular interactions (IntAct). He also led EMBL-EBI’s contribution to the Gene Ontology and is the current Director of Open Targets.
Rolf received his PhD from the University of Heidelberg in 1994, and has been at EMBL since 1987. His major contribution to the field of proteomics was recognised by the the Human Proteomics Organisation’s “Distinguished Achievement Award in Proteomics” in 2004 and his election to President of the Human Proteomics Organisation, which he held in 2007 and 2008. In 2012, he was elected as a member of EMBO and in 2015 he was elected to an ISCB (International Society for Computational Biology) fellow. Rolf also served over many years on a multitude of Editorial Boards and Scientific Advisory Boards.
apweiler [at] ebi.ac.uk
ORCID iD: 0000-0001-7078-200X
Tel: / Fax:+44 (0)1223 494 468
The Directors' office provides support to the Directors of EMBL-EBI, Rolf Apweiler and Ewan Birney, and for their projects. We are responsible for organising high-level visits to EMBL-EBI, and support reviews by our Advisory Committees, retreats for senior management, and EMBL management meetings in Hinxton. We administer the bi-weekly Strategy and Management Committee as well as the weekly Group and Team Leaders' meetings.
Open Targets aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community.
The goal of Open Targets is to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. It is a shared initiative between the European Bioinformatics Institute (EMBL-EBI), a global leader in the management, integration and analysis of public domain life science data; GSK, a leading, global pharmaceutical company; Biogen, one of the world’s oldest independent biotechnology companies; Takeda, a global, research and development-driven pharmaceutical company and the Wellcome Sanger Institute, a world-leading genomics institution with expertise in human genetics, cancer and infectious disease. Open Targets exists as a core operation within the Innovation Centre of EMBL-EBI's South Building on the Wellcome Genome Campus and involves staff from each of the institutions directly interacting there with access to the full normal scientific life of the campus. In addition it draws upon expertise from groups within the institutions spreading connections across the sites.